Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
A woman with her eyes closed, resting, photographed close up against a dark background.

Myasthenia Gravis Treatments Compared

8 FDA-approved drugs, plus 2 in development, side by side from the current prescribing labels. Newest label Nov 2026. Checked November 17, 2026.

The full Myasthenia Gravis guide, with open trials and help paying →

FcRn blockersVyvgart · Rystiggo · Imaavy
Complement C5 inhibitorsSoliris · Ultomiris · Zilbrysq · Klygefa
B-cell depletionUplizna

Eight targeted drugs are FDA-approved for generalized myasthenia gravis, and they fall into 3 groups.

  • Vyvgart, Rystiggo and Imaavy block FcRn to clear the harmful antibodies.
  • Soliris, Ultomiris, Zilbrysq and Klygefa block complement protein C5, carry a boxed warning for meningococcal infection and require vaccination.
  • Uplizna removes the B cells that make the antibodies.
  • Five are clinic infusions, Rystiggo is a pump infusion under the skin given by a clinician, Zilbrysq is a daily self-injection, Klygefa is a weekly shot that patients or caregivers can give, and Vyvgart also comes as a weekly under-the-skin version.
  • Bkemv and Epysqli, biosimilar versions of Soliris, are also approved for adults with AChR-positive generalized MG.
  • Most pivotal trials reported the average change in the MG-ADL daily-living score against placebo, with drug-minus-placebo differences of 1.5 to 2.6 points, while Vyvgart's label reports the share of responders, 68% against 30%. The trials used different time points and populations, so the numbers do not rank the drugs.

Latest for myasthenia gravis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Email me the day the FDA decides on Cemdisiran

You get one email when the decision is public, plus new trials and FDA news for this condition.

You'll get trial alerts and disease updates for Myasthenia Gravis, and you can turn either off anytime. We never share your email. Privacy policy

Side by side

8 approved myasthenia gravis treatments at a glance

How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.

Myasthenia Gravis treatments compared: route, schedule, approved use and approval date
DrugHow it is givenHow oftenApproved forFirst approved
eculizumab
Alexion (AstraZeneca)
IV infusion at a clinic every 2 weeksAbout 35 minutes per dose900mg weekly for 4 weeks, then 1,200mg at week 5, then 1,200mg every 2 weeksAdults and children 6 and older with generalized MG who are AChR antibody positiveOctober 23, 2017
efgartigimod alfa-fcab
argenx
IV infusion over 1 hour at a clinic, in cyclesAbout 60 minutes per dose10mg/kg once weekly for 4 weeks per cycle; next cycle timed by your doctor's evaluationAdults with generalized MG (current label is not limited by antibody status)December 17, 2021
rozanolixizumab-noli
UCB
Under-the-skin infusion by pump, given by a healthcare provider, in cyclesOnce weekly for 6 weeks per cycle, dose by body weight (420, 560 or 840mg); next cycle on evaluation, and the label says starting one sooner than 63 days after the last cycle began has not been tested for safetyAdults with generalized MG who are AChR or MuSK antibody positiveJune 26, 2023
zilucoplan
UCB
Daily shot under the skin, self-injected at homeOnce daily, dose by body weight (16.6, 23 or 32.4mg prefilled syringe)Adults with generalized MG who are AChR antibody positiveOctober 17, 2023
ravulizumab-cwvz
Alexion (AstraZeneca)
IV infusion at a clinic every 8 weeksWeight-based loading dose, then a maintenance dose 2 weeks later and every 8 weeks after thatAdults with generalized MG who are AChR antibody positiveApril 28, 2022
inebilizumab-cdon
Amgen
IV infusion at a clinic, about 90 minutes, twice a year after 2 starting dosesAbout 90 minutes per dose300mg, a second 300mg dose 2 weeks later, then 300mg every 6 monthsAdults with generalized MG who are AChR or MuSK antibody positiveDecember 11, 2025
nipocalimab-aahu
Johnson & Johnson
IV infusion at a clinic every 2 weeksAbout 15 minutes per dose30mg/kg starting dose over at least 30 minutes, then 15mg/kg every 2 weeks over at least 15 minutesAdults and children 12 and older with generalized MG who are AChR or MuSK antibody positiveApril 29, 2025
gefurulimab-gaks
Alexion (AstraZeneca)
Weekly shot under the skin, self-injected or given by a caregiverLoading dose on day 1 (600mg under 80kg, 900mg at 80kg or more), then 300mg or 600mg once a week from day 8Adults with generalized MG who are AChR antibody positiveNovember 13, 2026
The calendar

A year on each myasthenia gravis treatment

Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.

Soliris
Infusion, at a clinic
26 doses a year
Vyvgart
Infusion, at a clinic
10mg/kg once weekly for 4 weeks per cycle (no fixed yearly count)
Rystiggo
Infusion, at a clinic
Once weekly for 6 weeks per cycle, dose by body weight (420, 560 or 840mg) (no fixed yearly count)
Zilbrysq
Injection, at home
365 doses a year
Ultomiris
Infusion, at a clinic
7 doses a year
Uplizna
Infusion, at a clinic
2 doses a year
Imaavy
Infusion, at a clinic
26 doses a year
Klygefa
Injection, at home
52 doses a year

Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.

The evidence

What the pivotal myasthenia gravis trials showed

The primary result from the trial each FDA approval rests on, as reported on the label.

Myasthenia Gravis pivotal trial results by drug
DrugPivotal trialPrimary result
eculizumab
Alexion (AstraZeneca)
REGAIN (ECU-MG-301), 125 adults
Trial record or paper
MG-ADL fell 4.2 points vs 2.3 on placebo at week 26 (1.9-point difference)
efgartigimod alfa-fcab
argenx
ADAPT (Study 1), 167 adults
Trial record or paper
68% of AChR+ patients were MG-ADL responders in cycle 1 vs 30% on placebo
rozanolixizumab-noli
UCB
MycarinG (Study 1), 200 adults
Trial record or paper
MG-ADL fell 3.4 points vs 0.8 on placebo at day 43 (2.6-point difference)
zilucoplan
UCB
RAISE (Study 1), 174 adults
Trial record or paper
MG-ADL fell 4.39 points vs 2.30 on placebo at week 12 (2.09-point difference)
ravulizumab-cwvz
Alexion (AstraZeneca)
CHAMPION-MG (ALXN1210-MG-306), 175 adults
Trial record or paper
MG-ADL fell 3.1 points vs 1.4 on placebo at week 26 (1.6-point difference)
inebilizumab-cdon
Amgen
MINT (Study 3), 238 adults
Trial record or paper
MG-ADL fell 4.2 points vs 2.2 on placebo at week 26 (1.9-point difference)
nipocalimab-aahu
Johnson & Johnson
Vivacity-MG3 (gMG Study 1), 196 adults
Trial record or paper
MG-ADL fell 4.7 points vs 3.3 on placebo over weeks 22 to 24 (1.5-point difference)
gefurulimab-gaks
Alexion (AstraZeneca)
PREVAIL (Study 1), 260 adults
Trial record or paper
MG-ADL fell 4.2 points vs 2.6 on placebo at week 26 (1.6-point difference)
Safety

Myasthenia Gravis treatment side effects and warnings

Soliris, Zilbrysq, Ultomiris and Klygefa carry a boxed warning, the FDA's strongest. The rest list their main precautions. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.

Myasthenia Gravis treatments: most common side effects and key warnings from the FDA labels
DrugMost common side effectsKey warning
eculizumab
Alexion (AstraZeneca)
muscle and bone pain 15%, abdominal pain 8% and herpes simplex infections 8%Boxed warning Boxed warning: serious meningococcal infections. Meningococcal vaccination required; available only through a REMS program.
efgartigimod alfa-fcab
argenx
respiratory tract infections 33%, headache 32% and urinary tract infections 10%No boxed warning. Infections, hypersensitivity reactions including anaphylaxis, and infusion reactions.
rozanolixizumab-noli
UCB
headache 44%, infections 23% and diarrhea 20%No boxed warning. Infections, aseptic meningitis, hypersensitivity reactions.
zilucoplan
UCB
injection site reactions 29%, upper respiratory tract infections 14% and diarrhea 11%Boxed warning Boxed warning: serious meningococcal infections. Vaccination required; REMS program. Also pancreatitis and pancreatic cysts.
ravulizumab-cwvz
Alexion (AstraZeneca)
diarrhea 15%, upper respiratory tract infection 14% and dizziness 9%Boxed warning Boxed warning: serious meningococcal infections. Vaccination required; REMS program.
inebilizumab-cdon
Amgen
headache 15%, infusion-related reactions 10% and common cold symptoms 7%No boxed warning. Infusion reactions (premedication required), serious infections including hepatitis B reactivation, low immunoglobulin levels.
nipocalimab-aahu
Johnson & Johnson
respiratory tract infections 18%, swelling of the legs, feet or hands 12% and muscle spasms 12%No boxed warning. Infections, hypersensitivity reactions including anaphylaxis, infusion reactions.
gefurulimab-gaks
Alexion (AstraZeneca)
injection site reactions 12%, back pain 8% and vomiting 5%Boxed warning Boxed warning: serious meningococcal infections. Vaccination required; REMS program. Serious infections including 2 deaths occurred in the trial and its extension.
Not yet approved

Myasthenia gravis treatments in Phase 3 or under FDA review

Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.

Myasthenia Gravis drugs not FDA-approved
DrugStatusHow it works and is givenPivotal trialResult so farWhat is next
Regeneron (licensed from Alnylam)
Under FDA reviewas of November 7, 2026siRNA that lowers how much complement protein C5 the liver makesShot under the skin every 12 weeks (600mg in NIMBLE)NIMBLE, Phase 3, 284 peoplePrimary endpoint: MG-ADL change at week 24
ClinicalTrials.gov
Met primary endpoint: MG-ADL fell 4.5 points on cemdisiran vs 2.2 on placebo, 2.3 points more than placebo (Vu et al., The Lancet, 2026)FDA target action date in November 2026, on a day Regeneron has not disclosed
Regeneron press release, June 22, 2026
Kyverna Therapeutics
Phase 3as of November 17, 2026One-time CAR T-cell therapy made from a person's own T cells that clears CD19-carrying B cellsSingle infusion into a vein after 3 days of low-dose chemotherapyKYSA-6, Phase 2/3; Phase 3 part about 60 people randomized against continuing standard immune treatment, crossover allowed after 24 weeksPrimary endpoint: MG-ADL and QMG change at week 24
ClinicalTrials.gov
Phase 3 part enrolling. In the Phase 2 part, 7 people had mean drops of 8.3 points on MG-ADL and 11.7 on QMG at 24 weeks, with no comparison group (Kyverna, September 24, 2026)Kyverna said on November 12, 2026 that it expects Phase 3 enrollment to finish in mid-2027
Kyverna press release, September 24, 2026
Cost

Help paying for myasthenia gravis treatment

Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read
Follow Myasthenia Gravis treatment news by email

One email when the FDA acts on a Myasthenia Gravis treatment, a label changes or a new trial opens. Never a newsletter.

You'll get, for Myasthenia Gravis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Questions

Myasthenia Gravis treatment questions people ask

Imaavy vs Ultomiris: what is the difference for generalized myasthenia gravis?

Imaavy lowers the harmful antibodies themselves, while Ultomiris blocks complement, the part of the immune system those antibodies switch on to damage the nerve-muscle junction.

Who it is for: Imaavy is approved for adults and children 12 and older who are AChR or MuSK antibody positive. Ultomiris is for adults who are AChR antibody positive only.

How it is given: Imaavy is an IV infusion every 2 weeks after a larger starting dose, at least 15 minutes for each maintenance dose. Ultomiris is an IV infusion every 8 weeks after a weight-based loading dose and a first maintenance dose 2 weeks later.

Safety: Ultomiris carries a boxed warning for serious meningococcal infections, requires meningococcal vaccination and is available only through a REMS program. Imaavy has no boxed warning; its label warns about infections, allergic reactions including anaphylaxis, and infusion reactions.

Trial results: Imaavy lowered the MG-ADL daily-living score 1.5 points more than placebo over weeks 22 to 24, and Ultomiris 1.6 points more at week 26. The trials enrolled different patients, so these numbers do not show which drug works better.

More: Imaavy drug page and Ultomiris drug page

Source: FDA label for Imaavy, DailyMed, effective August 2026; FDA label for Ultomiris, DailyMed, effective October 2026

Imaavy vs Soliris: what is the difference for generalized myasthenia gravis?

Imaavy lowers the harmful antibodies, while Soliris blocks complement, and Soliris is the older, shorter-acting version of Ultomiris from the same company.

Who it is for: Imaavy covers AChR or MuSK antibody positive patients 12 and older. Soliris covers AChR antibody positive patients 6 and older, the youngest age of any myasthenia gravis drug on this page.

How it is given: Both are IV infusions every 2 weeks once treatment is underway. Imaavy starts with 1 larger dose; Soliris in adults starts with 4 weekly doses and a fifth dose at week 5.

Safety: Soliris carries the same boxed warning as Ultomiris for serious meningococcal infections, with required vaccination and a REMS program. Imaavy has no boxed warning.

Trial results: Soliris lowered the MG-ADL score 1.9 points more than placebo at week 26 in REGAIN, which enrolled people who had already failed 2 or more immunosuppressants. Imaavy lowered it 1.5 points more over weeks 22 to 24 in a broader population.

More: Imaavy drug page and Soliris drug page

Source: FDA label for Imaavy, DailyMed, effective August 2026; FDA label for Soliris, DailyMed, effective July 2026

Is Imaavy better than Ultomiris or Soliris?

No trial has compared them directly, so there is no evidence that one works better than the others for everyone.

What the trials show: Each drug beat placebo in its own trial by 1.5 to 1.9 points on the MG-ADL daily-living score, but the trials used different patients and time points, so the numbers cannot be ranked.

What usually decides it: Antibody type, since only Imaavy of the 3 is approved for MuSK-positive disease. Age, since Soliris starts at 6, Imaavy at 12 and Ultomiris at 18. How often you can get to an infusion center, every 2 weeks for Imaavy and Soliris against every 8 weeks for Ultomiris. Whether meningococcal vaccination and the infection risk of complement blockers fit your situation.

Next step: The table on this page puts all 8 approved myasthenia gravis drugs side by side for that conversation with your neurologist.

Source: FDA label for Imaavy, DailyMed, effective August 2026; FDA label for Ultomiris, DailyMed, effective October 2026; FDA label for Soliris, DailyMed, effective July 2026; ClinicalTrials.gov search for nipocalimab with ravulizumab or eculizumab, October 2026, no head-to-head trials found

What is the newest treatment for myasthenia gravis?

The newest FDA approval in generalized myasthenia gravis is Klygefa (gefurulimab), approved on November 13, 2026 for adults who are AChR antibody positive. It is a C5 complement blocker injected under the skin once a week after a weight-based loading dose. On May 8, 2026, the FDA expanded Vyvgart and Vyvgart Hytrulo to all adults with generalized MG, including people with no detectable AChR, MuSK or LRP4 antibodies. Before that, Uplizna (inebilizumab), already approved for other conditions, was approved for generalized MG on December 11, 2025, for adults who are AChR or MuSK antibody positive. Klygefa is also the newest drug whose first FDA approval was for generalized MG, after Imaavy (nipocalimab) on April 29, 2025. Regeneron's cemdisiran has an FDA decision due in November 2026, on a day Regeneron has not disclosed. The table on this page lists every approved drug with its trial results from the FDA label.

Which myasthenia gravis drugs can be taken at home?

Zilbrysq (zilucoplan) is a once-daily shot under the skin that patients give themselves from a prefilled syringe. The FDA approved a Zilbrysq autoinjector in October 2026, which UCB expects to be available in the first quarter of 2027. Klygefa (gefurulimab) is a once-weekly shot under the skin from a prefilled pen or syringe that patients or caregivers give after training. Vyvgart Hytrulo, the under-the-skin version of Vyvgart, can be self-injected once a week for 4 weeks per cycle. Rystiggo is also given under the skin but by a healthcare provider using a pump, and Soliris, Ultomiris, Uplizna and the IV form of Vyvgart are clinic infusions.

Which myasthenia gravis drugs have a boxed warning?

The 4 complement inhibitors, Soliris, Ultomiris, Zilbrysq and Klygefa, carry a boxed warning for serious meningococcal infections and require vaccination and enrollment in a safety program before the first dose. The FcRn blockers Vyvgart, Rystiggo and Imaavy, and the B-cell drug Uplizna, have no boxed warning; their main warnings are infections and infusion or hypersensitivity reactions.

Is Vyvgart better than Rystiggo?

No trial has compared them. In its own trial, 68% of AChR-positive patients on Vyvgart were MG-ADL responders in the first cycle against 30% on placebo. Rystiggo's trial reported a 2.6-point greater MG-ADL improvement than placebo at day 43. Vyvgart is given weekly for 4 weeks per cycle, Rystiggo for 6 weeks per cycle, and both repeat cycles on the doctor's judgment. Rystiggo's label also covers MuSK-positive disease; the current Vyvgart label covers generalized MG with no antibody qualifier.

Which myasthenia gravis treatment is given least often?

Uplizna, after 2 starting doses 2 weeks apart, is a clinic infusion once every 6 months. Ultomiris is every 8 weeks after a loading dose. The FcRn blockers run in cycles of weekly doses, Soliris and Imaavy are every 2 weeks, Klygefa is weekly, and Zilbrysq is daily.

Go deeper

More on Myasthenia Gravis at Trial Friend

Sources

Where every number on this page comes from

Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.

  1. Soliris (eculizumab) prescribing information, Alexion (AstraZeneca), label dated Jul 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  2. Vyvgart (efgartigimod alfa-fcab) prescribing information, argenx, label dated May 2026. DailyMed. Pivotal trial: publication
  3. Rystiggo (rozanolixizumab-noli) prescribing information, UCB, label dated Oct 2026. DailyMed. Pivotal trial: publication
  4. Zilbrysq (zilucoplan) prescribing information, UCB, label dated Feb 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  5. Ultomiris (ravulizumab-cwvz) prescribing information, Alexion (AstraZeneca), label dated Oct 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  6. Uplizna (inebilizumab-cdon) prescribing information, Amgen, label dated Sep 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  7. Imaavy (nipocalimab-aahu) prescribing information, Johnson & Johnson, label dated Aug 2026. DailyMed. Pivotal trial: publication
  8. Klygefa (gefurulimab-gaks) prescribing information, Alexion (AstraZeneca), label dated Nov 2026. FDA label. Pivotal trial: ClinicalTrials.gov
  9. cemdisiran, Regeneron (licensed from Alnylam): ClinicalTrials.gov record; Regeneron press release, June 22, 2026. Checked November 7, 2026.
  10. miv-cel (KYV-101), Kyverna Therapeutics: ClinicalTrials.gov record; Kyverna press release, September 24, 2026. Checked November 17, 2026.

This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.